AU2018207151B2 - Methods and compositions for evaluation and treatment of renal injury and renal failure based on C-C motif chemokine ligand 14 measurement - Google Patents

Methods and compositions for evaluation and treatment of renal injury and renal failure based on C-C motif chemokine ligand 14 measurement Download PDF

Info

Publication number
AU2018207151B2
AU2018207151B2 AU2018207151A AU2018207151A AU2018207151B2 AU 2018207151 B2 AU2018207151 B2 AU 2018207151B2 AU 2018207151 A AU2018207151 A AU 2018207151A AU 2018207151 A AU2018207151 A AU 2018207151A AU 2018207151 B2 AU2018207151 B2 AU 2018207151B2
Authority
AU
Australia
Prior art keywords
aki
subject
threshold
persistent
motif chemokine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018207151A
Other languages
English (en)
Other versions
AU2018207151A1 (en
Inventor
Donald CHALFIN
James Patrick Kampf
Paul Mcpherson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Astute Medical Inc
Original Assignee
Astute Medical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astute Medical Inc filed Critical Astute Medical Inc
Publication of AU2018207151A1 publication Critical patent/AU2018207151A1/en
Application granted granted Critical
Publication of AU2018207151B2 publication Critical patent/AU2018207151B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/521—Chemokines
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/34—Genitourinary disorders
    • G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
AU2018207151A 2017-01-12 2018-01-12 Methods and compositions for evaluation and treatment of renal injury and renal failure based on C-C motif chemokine ligand 14 measurement Active AU2018207151B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762445692P 2017-01-12 2017-01-12
US62/445,692 2017-01-12
PCT/US2018/013561 WO2018132702A1 (en) 2017-01-12 2018-01-12 Methods and compositions for evaluation and treatment of renal injury and renal failure based on c-c motif chemokine ligand 14 measurement

Publications (2)

Publication Number Publication Date
AU2018207151A1 AU2018207151A1 (en) 2019-07-18
AU2018207151B2 true AU2018207151B2 (en) 2024-02-29

Family

ID=62840533

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018207151A Active AU2018207151B2 (en) 2017-01-12 2018-01-12 Methods and compositions for evaluation and treatment of renal injury and renal failure based on C-C motif chemokine ligand 14 measurement

Country Status (8)

Country Link
US (2) US11353465B2 (https=)
EP (2) EP4063853A1 (https=)
JP (2) JP2020504157A (https=)
CN (2) CN110651187A (https=)
AU (1) AU2018207151B2 (https=)
CA (1) CA3049444A1 (https=)
MX (1) MX2019008260A (https=)
WO (1) WO2018132702A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4063853A1 (en) 2017-01-12 2022-09-28 Astute Medical, Inc. Methods and compositions for evaluation and treatment of renal injury and renal failure based on c-c motif chemokine ligand 14 measurement
US11891439B2 (en) 2017-12-28 2024-02-06 Astute Medical, Inc. Antibodies and assays for CCL14
CN114207436A (zh) * 2019-05-24 2022-03-18 机敏医药股份有限公司 基于c-c基序趋化因子配体14测量而评估和治疗肾损伤的方法
CA3145667A1 (en) * 2019-07-02 2021-01-07 Astute Medical, Inc Antibodies and assays for ccl14
EP4247395A4 (en) * 2020-11-18 2024-09-18 Astute Medical, Inc. Methods and compositions for treatment of renal injury and renal failure
CN113555122B (zh) * 2021-07-21 2024-04-26 中南大学湘雅二医院 一种重症脓毒症患者一过性和持续性aki的预测模型及其构建方法
CA3253529A1 (en) * 2022-03-03 2023-09-07 Astute Medical, Inc. METHODS AND COMPOSITIONS FOR EVALUATING AND TREATING PERSISTENT ACUTE RENAL INJURY BASED ON A C-C MOTIFYING CHEMOKIN LIGAND MEASUREMENT 14

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016064877A2 (en) * 2014-10-20 2016-04-28 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5028535A (en) 1989-01-10 1991-07-02 Biosite Diagnostics, Inc. Threshold ligand-receptor assay
US5939272A (en) 1989-01-10 1999-08-17 Biosite Diagnostics Incorporated Non-competitive threshold ligand-receptor assays
US5922615A (en) 1990-03-12 1999-07-13 Biosite Diagnostics Incorporated Assay devices comprising a porous capture membrane in fluid-withdrawing contact with a nonabsorbent capillary network
CA2072758A1 (en) 1990-09-14 1992-03-15 Kenneth Francis Buechler Antibodies to complexes of ligand receptors and ligands and their utility in ligand-receptor assays
US5955377A (en) 1991-02-11 1999-09-21 Biostar, Inc. Methods and kits for the amplification of thin film based assays
AU1772992A (en) 1991-04-10 1992-11-17 Biosite Diagnostics Incorporated Crosstalk inhibitors and their uses
JP3290988B2 (ja) 1991-04-11 2002-06-10 バイオサイト・ダイアグノスティックス・インコーポレイテッド 多重リガンドを同時検出する新規接合体及び検定法
US5885527A (en) 1992-05-21 1999-03-23 Biosite Diagnostics, Inc. Diagnostic devices and apparatus for the controlled movement of reagents without membrances
US6143576A (en) 1992-05-21 2000-11-07 Biosite Diagnostics, Inc. Non-porous diagnostic devices for the controlled movement of reagents
US5494829A (en) 1992-07-31 1996-02-27 Biostar, Inc. Devices and methods for detection of an analyte based upon light interference
US5824799A (en) 1993-09-24 1998-10-20 Biosite Diagnostics Incorporated Hybrid phthalocyanine derivatives and their uses
US6811773B1 (en) * 1993-12-22 2004-11-02 Human Genome Sciences, Inc. Human monocyte colony inhibitory factor (M-CIF) polypeptides
US6113855A (en) 1996-11-15 2000-09-05 Biosite Diagnostics, Inc. Devices comprising multiple capillarity inducing surfaces
US5947124A (en) 1997-03-11 1999-09-07 Biosite Diagnostics Incorporated Diagnostic for determining the time of a heart attack
US6057098A (en) 1997-04-04 2000-05-02 Biosite Diagnostics, Inc. Polyvalent display libraries
AU2003223172A1 (en) 2002-02-12 2003-09-04 Quark Biotech, Inc. Use of the axl receptor for diagnosis and treatment of renal disease
EP1915614A4 (en) * 2005-07-21 2009-03-25 Univ Johns Hopkins METHOD FOR DETECTING AND TREATING AN ACUTE KIDNEY INJURY
EP2479569A3 (en) 2007-03-26 2012-09-26 Novartis AG Predictive renal safety biomarkers and biomarker signatures to monitor kidney function
US20110059537A1 (en) * 2007-09-20 2011-03-10 Caritas St. Elizabeth's Medical Center Of Boston, Inc. Method for estimating risk of acute kidney injury
EP2324354B1 (en) 2008-08-29 2014-07-16 Astute Medical, Inc. Methods for prognosis of acute renal failure
CA2740923A1 (en) 2008-10-21 2010-04-29 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
EP2462437A4 (en) 2009-08-07 2013-01-30 Rules Based Medicine Inc METHOD AND DEVICES FOR DETECTING DIABETIC NEPHROPATHY AND ASSOCIATED DISEASES THEREOF
NZ600160A (en) 2009-11-07 2014-05-30 Astute Medical Inc Methods and compositions for diagnosis and prognosis of renal injury and renal failure
US20120156701A1 (en) 2009-12-20 2012-06-21 Joseph Anderberg Methods and compositions for diagnosis and prognosis of renal injury and renal failure
WO2011075744A1 (en) * 2009-12-20 2011-06-23 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
AU2011213684B2 (en) 2010-02-05 2014-11-20 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
NZ606124A (en) 2010-06-23 2015-05-29 Astute Medical Inc Methods and compositions for diagnosis and prognosis of renal injury and renal failure
IN2012MN02812A (https=) 2010-06-23 2015-05-22 Astute Medical Inc
NZ605698A (en) 2010-06-23 2015-03-27 Astute Medical Inc Methods and compositions for diagnosis and prognosis of renal injury and renal failure
WO2012136548A1 (en) 2011-04-04 2012-10-11 Universiteit Gent Biomarkers for acute kidney injury
PT2748605T (pt) 2011-08-26 2019-05-03 Astute Medical Inc Processos e composições para o diagnóstico e o prognóstico de lesões renais e de insuficiência renal
US10935548B2 (en) 2011-12-08 2021-03-02 Astute Medical, Inc. Methods for diagnosis and prognosis of renal injury and renal failure using insulin-like growth factor-binding protein 7 and metalloproteinase inhibitor 2
WO2013096740A1 (en) 2011-12-21 2013-06-27 Alere San Diego Inc. Methods and compositions for assigning likelihood of chronic kidney disease progression
EP4063853A1 (en) 2017-01-12 2022-09-28 Astute Medical, Inc. Methods and compositions for evaluation and treatment of renal injury and renal failure based on c-c motif chemokine ligand 14 measurement

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016064877A2 (en) * 2014-10-20 2016-04-28 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure

Also Published As

Publication number Publication date
AU2018207151A1 (en) 2019-07-18
CA3049444A1 (en) 2018-07-19
WO2018132702A1 (en) 2018-07-19
JP2020504157A (ja) 2020-02-06
EP4063853A1 (en) 2022-09-28
JP2022091846A (ja) 2022-06-21
CN110651187A (zh) 2020-01-03
EP3568695A1 (en) 2019-11-20
MX2019008260A (es) 2020-01-27
US20190339289A1 (en) 2019-11-07
US20230025225A1 (en) 2023-01-26
CN114088950A (zh) 2022-02-25
US11353465B2 (en) 2022-06-07
EP3568695A4 (en) 2020-12-16
US12203944B2 (en) 2025-01-21

Similar Documents

Publication Publication Date Title
US12019080B2 (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
AU2009285550B2 (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
US12203944B2 (en) Methods and compositions for evaluation and treatment of renal injury and renal failure based on C-C motif chemokine ligand 14 measurement
AU2010210540B2 (en) Methods and compositions for diagnosis and prognosis of renal injury and failure
AU2010210535B2 (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
US11333671B2 (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
CA2743253A1 (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
AU2010295287A1 (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
AU2012312907A1 (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
AU2010286559A1 (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
CA2770393A1 (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
AU2012282918A1 (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
AU2015200953A1 (en) Methods and composition for diagnosis and prognosis of renal injury and renal failure
US12560616B2 (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
AU2012282917A1 (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
AU2013226181A1 (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
AU2013296231A1 (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
AU2013226184A1 (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
AU2014212609A1 (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)